Aragon Pharmaceuticals Gets $8M

La Jolla-based Aragon Pharmaceuticals reported Wednesday that it has raised $8M in a Series A financing. The firm, which is focused on small molecule therapeutics for treating hormone-resistant cancers, said that the financing was led by The Column Group and OrbiMed Advisors. The company said it is initially focused on prostate and breast cancer. Aragon's technology comes from research developed at Memorial Sloan Kettering Cancer Center, the Howard Hughes Medical Institute, and UCLA. More information »